73.96 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||73.81 - 76.08|
|52 Week Range||56.21 - 84.49|
|PE Ratio (TTM)||27.97|
|Earnings Date||May 2, 2018 - May 7, 2018|
|Forward Dividend & Yield||0.28 (0.36%)|
|1y Target Est||83.86|
STERIS' (STE) string of six buyouts in fiscal 2018 keeps us upbeat about the stock. The same is expected to strengthen its Healthcare Specialty Services and Applied Sterilization Technologies arms.
Davita's kidney care unit is gaining prominence worldwide. However, the company is grappling with labor-union woes in California and Ohio.
Thermo Fisher Scientific (TMO) forges ahead with initiatives to strengthen its hold in the high-potential human identification market.
BioScrip's (BIOS) strategy to specifically focus on core revenue mix hurts overall growth. However, the company's core infusion business remains strong.
Orthofix's (OFIX) latest deal to boost Spine Fixation portfolio and strengthen hold in the high-potential artificial disc market buoys optimism.
The acquisition of Sirtex will fortify Varian Medical's (VAR) footprint in Australia. The transaction is likely to close in late May 2018.
Medtronic, (MDT) presenting favorable results from the studies based on the CoreValve TAVR system might boost the top line, with increased uptake of the product.
Laborie Medical Technologies will buy all of the outstanding shares of Cogentix Medical (CGNT) for a net worth of $239 million.
Illumina (ILMN) successfully broadens base by enriching its portfolio of sequencing products and building strategic partnerships with therapeutic and diagnostic service providers.
IDEXX Laboratories (IDXX) continues to boost investor confidence in strong companion animal business along with attractive global prospects.
Orthofix (OFIX) vouches for PhysioStim's efficiency, claiming the devices to lead the U.S. market of prescribed bone growth stimulators combined with spinal fusion stimulators.
Quest Diagnostics' (DGX) upgraded long-term guidance based on its new and extended two-point strategy looks promising. However, it expresses resentment against the recent PAMA-related CMS proposal.
Sturdy performance of NuVasive's (NUVA) international business with more than 20% growth for the fifth consecutive quarter raises optimism among investors